The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein
Open accessAbstract
Soluble amyloid-β oligomers (Aβo) trigger Alzheimer's disease (AD) pathophysiology and bind with high affinity to cellular prion protein (PrP(C)). At the postsynaptic density (PSD), extracellular Aβo bound to lipid-anchored PrP(C) activates intracellular Fyn kinase to disrupt synapses. Here, we screened transmembrane PSD proteins heterologously for the ability to couple Aβo-PrP(C) with Fyn. Only coexpression of the metabotropic glutamate receptor, mGluR5, allowed PrP(C)-bound Aβo to activate Fyn. PrP(C) and mGluR5 interact physically, and cytoplasmic Fyn forms a complex with mGluR5. Aβo-PrP(C) generates mGluR5-mediated increases of intracellular calcium in Xenopus oocytes and in neurons, and the latter is also driven by human AD brain extracts. In addition, signaling by Aβo-PrP(C)-mGluR5 complexes mediates eEF2 phosphorylation and dendritic spine loss. For mice expressing familial AD transgenes, mGluR5 antagonism reverses deficits in learning, memory, and synapse density. Thus, Aβo-PrP(C) complexes at the neuronal surface activate mGluR5 to disrupt neuronal function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ oligomers can drive additional vicious cycles by stimulating metabotropic glutamate receptor 5 (mGluR5)146,147, which activates feedforward Ca2+–cAMP signaling and drive tau phosphorylation (Fig. 5, brown).”
From Stress weakens prefrontal networks: molecular insults to higher cognition (2015) · cites this paper as [147]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Amyloid-β oligomer binding results in aberrant neuronal signaling and the endocytosis of the dysfunctional synapse into the cell [126,127].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the Aβ binding candidates, cellular prion protein (PrPc) represents the most studied, either alone or through a complex with mGluR5 [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most studied binding partner is the PrPc, which through a cascade involving a complex with mGluR5 may lead to toxicity independently or via tau [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Amyloid-β oligomers bind to a protein complex comprised of cellular prion protein (PrPc) along with other proteins including leukocyte immunoglobulin-like receptor subfamily B2/paired immunoglobulin-like type 2 receptor B (LilrB2), and possibly also Nogo-66 receptor 1 (Nogo-1), low-affinity nerve growth factor (NGF) receptor [125] (Figure 3), and the metabotropic glutamate receptor 5 [126].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larson, M. E., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 290
RetractedTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Self-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Impaired Long-Term Potentiation, Spatial Learning, and Hippocampal Development in fyn Mutant Mice
Grant, S. G. N., O’Dell, T. J., Karl, K. A., Stein, P. L., Soriano, P. M., & Kandel, E. R. (1992) · Science · doi:10.1126/science.1361685 · Cited by 1,160
Proximal events in Wnt signal transduction
Angers, S., & Moon, R. T. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2717 · Cited by 1,135
Luján, R., Nusser, Z., Roberts, J. D. B., Shigemoto, R., & Somogyi, P. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01611.x · Cited by 874
Flagged first, then by citations
1 of the 65 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 581
Wang, C., Liu, M., Zhang, D., Li, P., Wang, D., Sun, S., & Wei, W. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.340857 · Cited by 11
mGluR-dependent plasticity in rodent models of Alzheimer’s disease
Valdivia, G., Ardiles, Á. O., Idowu, A., Salazar, C., Lee, H., Gallagher, M., Palacios, A. G., & Kirkwood, A. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1123294 · Cited by 11
Li, J., Liu, Y., Yin, C., Zeng, Y., & Mei, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102468 · Cited by 13
Liu, Y., Song, S., Li, X., Wang, J., Bao, Y., Wang, X., Lian, L., Liu, X., & Ma, W. (2024) · Pharmaceuticals · doi:10.3390/ph17091231 · Cited by 13
Choquet, D., Opazo, P., & Zhang, H. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00470-z · Cited by 11
Prion protein — mediator of toxicity in multiple proteinopathies
Ayers, J. I., & Prusiner, S. B. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0332-8 · Cited by 11
Actor-Engel, H. S., Schwartz, S. L., Crosby, K. C., Sinnen, B. L., Prikhodko, O., Ramsay, H. J., Bourne, J. N., Winborn, C. S., Lucas, A., Smith, K. R., et al. (2021) · eNeuro · doi:10.1523/eneuro.0416-21.2021 · Cited by 11
Hu, C., Chen, C., Xia, Y., Chen, J., Yang, W., Wang, L., Chen, D., Wu, Y.-Z., Fan, Q., Jia, X.-X., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.844378 · Cited by 11
Kalinowska, M., & Francesconi, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150515234434 · Cited by 11
Kootar, S., Frandemiche, M., Dhib, G., Mouska, X., Lorivel, T., Poupon, G., Hunt, H., Tronche, F., Bethus, I., Barik, J., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.07.001 · Cited by 11
Matsubara, T., Satoh, K., Homma, T., Nakagaki, T., Yamaguchi, N., Atarashi, R., Sudo, Y., Uezono, Y., Ishibashi, D., & Nishida, N. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.102 · Cited by 10
Béland, M., & Roucou, X. (2013) · Prion · doi:10.4161/pri.27438 · Cited by 12
Show Me Your Friends and I Tell You Who You Are: The Many Facets of Prion Protein in Stroke
Puig, B., Yang-Seeger, D., Brenna, S., Altmeppen, H. C., & Magnus, T. U. (2020) · Cells · doi:10.3390/cells9071609 · Cited by 11
Behroozi, Z., Askarpour, H., & Baghcheghi, Y. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261415807 · Cited by 10
Zhang, R., Xu, H., Jiang, J., Han, R.-W., Chang, M., Peng, Y., Wang, Y., & Wang, R. (2015) · Brain Research · doi:10.1016/j.brainres.2015.10.028 · Cited by 11
Involvement of IL-10R/STAT3 pathway in amyloid β clearance by microlgia in Alzheimer's disease
Liu, H., Zhou, Y., & Song, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108263 · Cited by 9
The Implication of Glial Metabotropic Glutamate Receptors in Alzheimer’s Disease
de Lima, I. B. Q., & Ribeiro, F. M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x20666211223140303 · Cited by 9
Derailed Intraneuronal Signalling Drives Pathogenesis in Sporadic and Familial Alzheimer’s Disease
Dooren, T. V., Princen, K., Witte, K. D., & Griffioen, G. (2014) · BioMed Research International · doi:10.1155/2014/167024 · Cited by 9
MicroRNA Alterations in a Tg501 Mouse Model of Prion Disease
Toivonen, J. M., Sánz-Rubio, D., López-Pérez, Ó., Marín‐Moreno, A., Bolea, R., Osta, R., Badiola, J. J., Zaragoza, P., Espinosa, J. C., Torres, J. M., et al. (2020) · Biomolecules · doi:10.3390/biom10060908 · Cited by 9
The IDIP framework for assessing protein function and its application to the prion protein
Schmitt‐Ulms, G., Mehrabian, M., Williams, D., & Ehsani, S. (2021) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12731 · Cited by 10
Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease
Zahratka, J. A., Shao, Y. Y., Shaw, M. L., Todd, K. W., Formica, S. V., Khrestian, M., Montine, T. J., Leverenz, J. B., & Bekris, L. M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.001 · Cited by 9
Genome wide association study of clinical duration and age at onset of sporadic CJD
Hummerich, H., Speedy, H. E., Campbell, T., Darwent, L., Hill, E., Collins, S. J., Stehmann, C., Kovács, G. G., Geschwind, M. D., Frontzek, K., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304528 · Cited by 8
Al-Jaf, S., Soliman, A. Y., EL‐Yazbi, A. F., & Abd‐Elrahman, K. S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00614 · Cited by 8
Lin, J., Callender, J. A., Mayfield, J. E., McClatchy, D. B., Ojeda-Juárez, D., Pourhamzeh, M., Soldau, K., Kurt, T. D., Danque, G. A., Khuu, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186432 · Cited by 8
Salardini, E., O’Dell, R. S., Tchorz, E., Nabulsi, N., Huang, Y. H., Carson, R. E., van Dyck, C. H., & Mecca, A. P. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01739-1 · Cited by 8
The importance of prion research
Eid, S., Lee, S., Verkuyl, C. E., Almanza, D. L., Hanna, J., Shenouda, S., Belotserkovsky, A., Zhao, W., & Watts, J. C. (2024) · Biochemistry and Cell Biology · doi:10.1139/bcb-2024-0018 · Cited by 8
Fioriti, L., Wijesekara, N., Argyrousi, E. K., Matsuzaki, S., Takamura, H., Satoh, K., Han, K., Yamauchi, H., Staniszewski, A., Acquarone, E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70030 · Cited by 8
Oligomeropathies, inflammation and prion protein binding
Forloni, G., Vitola, P. L., & Balducci, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.822420 · Cited by 8
Nong, Y., Kim, J. S., Jia, L., Arancio, O., & Wang, Q. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251342273 · Cited by 8
Intrinsic toxicity of the cellular prion protein is regulated by its conserved central region
Roseman, G. P., Wu, B., Wadolkowski, M. A., Harris, D. A., & Millhauser, G. L. (2020) · The FASEB Journal · doi:10.1096/fj.201902749rr · Cited by 7
Hofmann, C., Sander, A., Wang, X. X., Buerge, M., Jungwirth, B., Borgstedt, L., Kreuzer, M., Kopp, C., Schorpp, K., Hadian, K., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201185 · Cited by 7
What Are the Roles of Cellular Prion Protein in Normal and Pathologic Conditions?
Benarroch, E. E. (2024) · Neurology · doi:10.1212/wnl.0000000000209272 · Cited by 8
Miller, B., Moreno, N., Gutierrez, B. A., & Limón, A. (2022) · Membranes · doi:10.3390/membranes12100931 · Cited by 7
Emerging concepts towards a translational framework in Alzheimer’s disease
Cozachenco, D., Zimmer, E. R., & Lourenco, M. V. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105246 · Cited by 7
Mallozzi, C., Pepponi, R., Gaddini, L., Casella, I., Chiodi, V., Popoli, P., & Domenici, M. R. (2023) · Biomolecules · doi:10.3390/biom13091350 · Cited by 7
Kaar, A., Weir, M. P., & Rae, M. G. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137664 · Cited by 8
A Multi-Marker Genetic Association Test Based on the Rasch Model Applied to Alzheimer’s Disease
Wang, W., Mandel, J., Bouaziz, J., Commenges, D., Nabirotchkine, S., Chumakov, I. M., Cohen, D., Guedj, M., & Initiative, T. A. D. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138223 · Cited by 7
Common therapeutic strategies for prion and Alzheimer’s diseases
Elezgarai, S. R., & Biasini, E. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0190 · Cited by 7
Yang, T., Zhang, D., Huang, H., Liu, F., Wu, J., Ma, X., Liu, S., Huang, M., Zhou, Y., & Shen, Y. (2025) · Brain · doi:10.1093/brain/awaf186 · Cited by 10
Liu, Y., Tuttle, M. D., Kostylev, M. A., Roseman, G. P., Zilm, K. W., & Strittmatter, S. M. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10590 · Cited by 6
Self-citationBorgstedt, L., Blobner, M., Musiol, M., Bratke, S., Syryca, F., Rammes, G., Jungwirth, B., & Schmid, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242989 · Cited by 6
Rivas-Santisteban, R., Raïch, I., Aguinaga, D., Saura, C., Franco, R., & Navarro, G. (2023) · Cells · doi:10.3390/cells12020283 · Cited by 2
Metabotropic glutamate receptor function and regulation of sleep-wake cycles
Holter, K. M., Pierce, B. E., & Gould, R. W. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2022.11.002 · Cited by 6
Yang, S.-T., Wang, M., Galvin, V. C., Yang, Y., & Arnsten, A. F. T. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05661-2 · Cited by 6
Wısnıewskı, T., & Goñi, F. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63945-5.00023-4 · Cited by 6
Alzheimer’s Disease, β-Amyloid Peptides, and Ubiquitin-Proteasome System: Nutritherapeutic Insights
Simon, P. Y. R., & David, R. (2025) · Neurodegenerative Diseases · doi:10.1159/000545170 · Cited by 5
Prabhu, S. V., & Singh, S. K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191105112800 · Cited by 5
Mercer, R. C. C., McDonald, A. J., Bove‐Fenderson, E., Fang, C., Wu, B., & Harris, D. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00002-x · Cited by 5
Stachowicz, K., Pańczyszyn-Trzewik, P., Sowa-Kućma, M., & Misztak, P. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102347 · Cited by 5
Transmissible Spongiform Encephalopathies
Wısnıewskı, T., & Goñi, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-33189-8_7 · Cited by 5
Lima‐Filho, R. A. S., & Oliveira, M. M. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.3307-17.2018 · Cited by 5
The involvement of the mGluR5-mediated JNK signaling pathway in rats with diabetic retinopathy
Zhu, Y., Zuo, G., Wang, Q., Chen, X.-M., Cheng, J.-K., & Zhang, S. (2019) · International Ophthalmology · doi:10.1007/s10792-018-01061-w · Cited by 5
Beckman, D., & Linden, R. (2016) · Prion · doi:10.1080/19336896.2016.1152437 · Cited by 5
Sleep is bi-directionally modified by amyloid beta oligomersPreprint
Özcan, G. G., Lim, S., Leighton, P. L. A., Allison, W. T., & Rihel, J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/610014 · Cited by 5
Cellular Prion Protein and Amyloid – β Oligomers in Alzheimer's Disease – There Are Connections?Preprint
Hachiya, N., Fułek, M., Zajączkowska, K., Kurpas, D., Trypka, E., & Leszek, J. (2021) · Preprints.org · doi:10.20944/preprints202105.0032.v1 · Cited by 5
The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma
Caniceiro, A. B., Agostinho, S. P., Piochi, L. F., Rosário‐Ferreira, N., & Moreira, I. S. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71131 · Cited by 4
A New Bistable Switch Model of Alzheimer’s Disease Pathogenesis
Burlando, B., Losacco, S., Villa, V., Fedele, E., & Ricciarelli, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137061 · Cited by 4
N-terminal truncation of peptide effects on human serum albumin and beta amyloid peptide interaction
Zare, M. S., Bozorgmehr, M. R., Mohseni, S., & Beyramabadi, S. A. (2023) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2023.101004 · Cited by 4
Sánchez-Fernández, N., Gómez-Acero, L., Castañé, A., Adell, A., Campa, L., Bonaventura, J., Brito, V., Ginés, S., Queiróz, F., Silva, H. B. L., et al. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00439 · Cited by 5
Emerging Mechanisms in Alzheimer’s Disease and Their Therapeutic Implications
Strittmatter, S. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.002 · Cited by 4
Self-citationLee, J., & Kwag, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00901-9 · Cited by 4
Amyloid pathology induces dysfunction of systemic neurotransmission in aged APPswe/PS2 mice
Oh, S. J., Lee, N., Nam, K. R., Kang, K. J., Han, S. J., Lee, K. C., Lee, Y. J., & Choi, J. Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.930613 · Cited by 4
Lou, Y., Lv, Y., Li, Z., Kang, Y., Hou, M., Fu, Z., Lu, L., Liu, L., Cai, Z., Qi, Z., et al. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230113152622 · Cited by 4
Computer-Aided Drug Design Approaches to Study Key Therapeutic Targets in Alzheimer’s Disease
Lemos, A., Melo, R., Moreira, I. S., & Cordeiro, M. N. D. S. (2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7_3 · Cited by 4
Suppiramaniam, V. D., Bloemer, J., Reed, M. N., & Bhattacharya, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65382-5 · Cited by 4
An inter-domain regulatory mechanism controls toxic activities of PrPC
McDonald, A. J., Wu, B., & Harris, D. A. (2017) · Prion · doi:10.1080/19336896.2017.1384894 · Cited by 4
Stamenković, V., Lautz, J. D., Harsh, F. M., & Smith, S. E. P. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02418-7 · Cited by 3
Pharmacological characterisation of allosteric modulators at human mGlu5
Razzak, M. A., Tran, K., McCague, R., Sengmany, K., Kos, J., Langiu, M., Li, B., Hellyer, S. D., & Gregory, K. J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117030 · Cited by 3
Zhang, M., Rehman, M. U., & Long, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117380 · Cited by 5
The role of PrPc in Alzheimer's disease related Amyloid-β hypothesis: a systematic review
Gomes, T. A. M., Silva, M. P. D. S., Gomes, M. P. S. M., Barh, D., Azevedo, V., & Dutra, J. D. C. F. (2023) · Brain Disorders · doi:10.1016/j.dscb.2023.100098 · Cited by 3
Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia
Tanwir, S. E., & Kumar, A. (2019) · Open Journal of Medicinal Chemistry · doi:10.4236/ojmc.2019.91001 · Cited by 3
Group I metabotropic glutamate receptors (mGluR1/5) and neurodegenerative diseases
Solntseva, E. I., Rogozin, P. D., & Skrebitsky, V. G. (2019) · Annals of Clinical and Experimental Neurology · doi:10.25692/acen.2019.4.8 · Cited by 3
Datta, D. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad134 · Cited by 3
Purro, S. A., Farmer, M., Noble, E., Sarell, C. J., Powell, M., Yip, D. C.-M., Giggins, L., Zakka, L., Thomas, D. X., Farrow, M. A., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294465 · Cited by 3
Human DDIT4L intron retention contributes to cognitive impairment and amyloid plaque formation
Li, K., Shi, H., Li, Z., You, P., Pan, J., Cai, Y.-C., Li, J.-W., Ma, X.-F., Zhang, S., Diao, L., et al. (2025) · Cell Discovery · doi:10.1038/s41421-024-00759-9 · Cited by 3
Abd‐Elrahman, K. S., Albaker, A. B., de Souza, J. M., Ribeiro, F. M., Schlossmacher, M. G., Tiberi, M., Hamilton, A., & Ferguson, S. S. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/803262 · Cited by 3
Positron Emission Tomography in Animal Models of Alzheimer’s Disease AmyloidosisPreprint
Ni, R. (2021) · Preprints.org · doi:10.20944/preprints202110.0222.v1 · Cited by 2
Wang, Y., Mohammadi, B., Hartmann, C., Hartmann, K., Thies, E., Matamoros‐Angles, A., Fang, C., Harris, D. A., Tatzelt, J., Altmeppen, H. C., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02235-9 · Cited by 2
Self-citationDecoding the mechanisms of amyloid-β in synaptic toxicity
Toruński, P., Pizzirusso, G., Winblad, B. G., & Arroyo‐García, L. E. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261424292 · Cited by 2
Therapeutic Importance of Curcumin in Neurological Disorders Other Than Alzheimer Disease
Farooqui, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-15889-1_8 · Cited by 2
Neurochemical Aspects of Alzheimer Disease
Farooqui, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-15889-1_1 · Cited by 2
Interaction of C-terminal Truncated Beta-amyloid Peptides with Human Serum Albumin
Firozabadi, D. A., Bozorgmehr, M. R., Beyramabadi, S. A., & Mohseni, S. (2023) · Current Proteomics · doi:10.2174/0115701646243074231113071548 · Cited by 2
Yang, Q., Zhou, X., & Ma, T. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.05.009 · Cited by 2
“Current and emerging drug therapies in Alzheimer’s disease: A pathophysiological Perspective”
Aparajita, A., Jain, U., & Srivastava, P. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.078 · Cited by 2
Zhang, C., Liu, X., Wang, J., Zhou, G., Geng, B., Hu, M., & Tang, Q. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107312 · Cited by 2
Targeting Aβ Receptors to Modify Alzheimer’s Disease Progression
Haas, L. T., & Strittmatter, S. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00008-3 · Cited by 2
Self-citationRubenstein, R., Petersen, R. B., & Wısnıewskı, T. (2016) · ASM Press eBooks · doi:10.1128/9781555818722.ch71 · Cited by 2
Inhibitors of Tau-Phosphorylating Kinases
Fallacara, A. L., Trist, I. M. L., Schenone, S., & Botta, M. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_17 · Cited by 2
Hippolyte, A., & Vernis, L. (2019) · médecine/sciences · doi:10.1051/medsci/2019174 · Cited by 2
Tam, J. H. K., & Pasternak, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00004-5 · Cited by 2
Liquid–liquid phase separation in synaptopathies
Jiang, H., & Wu, H. (2023) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.21 · Cited by 2
Post-translational modifications in prion diseases
Bizingre, C., Bianchi, C., Baudry, A., Alleaume‐Butaux, A., Schneider, B., & Pietri, M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1405415 · Cited by 2
Prion protein in exosomes: partnering Aβ peptides and driving fibrilization
Martins, V. R., & Prado, M. A. M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13541 · Cited by 2
Pickett, E. K., Herrmann, A. G., McQueen, J., Abt, K. M., Dando, O., Tulloch, J., Jain, P., Dunnett, S. L., Sohrabi, S., Fjeldstad, M. P., et al. (2018) · SSRN Electronic Journal · doi:10.1101/393405 · Cited by 2
Orri, E. V., Kasuga, K., Tyan, S.-H., Chiang, K., da Silva, S. V., Bushong, E. A., DeLoach, K. E., Ling, I., Luo, L., Ellisman, M. H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.18.210344 · Cited by 2
Aging-Dependent Loss of Connectivity in Alzheimer’s Model Mice with Rescue by mGluR5 ModulatorPreprint
Mandino, F., Shen, X., Desrosiers-Grégoire, G., O’Connor, D. A., Mukherjee, B., Owens, A., Qu, A., Onofrey, J. A., Papademetris, X., Chakravarty, M. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.15.571715 · Cited by 2
Self-citationNarayan, V. P., Tanwar, V., Andersen, J. K., & Kapahi, P. (2024) · Research Square · doi:10.21203/rs.3.rs-4351073/v1 · Cited by 2
Amyloid polymorphs and pathological diversities
Melki, R. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105335 · Cited by 1
Luo, H., de Velasco, E. M. F., Kim, J. J., Yang, P., Mermelstein, P. G., Bonventre, J. V., Cooke, P. S., & Wickman, K. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00776-7 · Cited by 1
Zhang, X., Zhao, Y., Chen, X., Shen, W., Huang, L., & Tan, T. (2025) · Glia · doi:10.1002/glia.70130 · Cited by 1
Metadata
- Authors
- Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., Gunther, E. C., Nygaard, H. B., & Strittmatter, S. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Strittmatter, Stephen M.
- ORCID
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 79
- Issue
- 5
- Pages
- 887-902
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC3768018
- OpenAlex
- W2061342941
- Cited by
- 572
- References
- 65
- Citations by year
- 2026: 28 · 2025: 31 · 2024: 29 · 2023: 35 · 2022: 38 · 2021: 32 · 2020: 59 · 2019: 45 · 2018: 46 · 2017: 63 · 2016: 59 · 2015: 58 · 2014: 45 · 2013: 4
- FWCI
- 34.36
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-10-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institute on Aging (P30AG008051, R01AG034924)
- National Institute of General Medical Sciences (T32GM007223, T32GM007205)
- National Institute of Neurological Disorders and Stroke (R01NS074319, R01NS073502, R01NS080388)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- metabotropic glutamate receptor 5, amyloid-beta oligomers, cellular prion protein, Alzheimer's disease, Fyn, postsynaptic density, intracellular calcium signaling, eEF2 phosphorylation, dendritic spine loss, learning and memory impairment, synaptic loss
- MeSH terms
- Alzheimer Disease, Animals, Calcium, Cells, Cultured, Humans, Neurons, Oocytes, Phosphorylation, Xenopus, Signal Transduction, Amyloid beta-Peptides, Receptors, Metabotropic Glutamate, PrPC Proteins, Proto-Oncogene Proteins c-fyn, Mice, Elongation Factor 2 Kinase, HEK293 Cells, Post-Synaptic Density, Receptor, Metabotropic Glutamate 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
